University hospital Tübingen
Tübingen, 72076, Germany
Location status: Recruiting
NCT Number: NCT04208126
This trial is a prospective randomized multicenter trial that assigns patients to either a treatment for Acute Respiratory Distress Syndrome (ARDS) with an Extracorporal Membrane Oxygenation (ECMO) immediately after admission to the intensive care unit or conservative treatment. The later can undergo ECMO following failure of conservative therapy as a rescue therapy. Patients will be included within 24 hours of the onset of symptoms of ARDS and will be randomized according to standard procedure. Follow-up will be performed until day 90 after study inclusion.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Tübingen, 72076, Germany
Location status: Recruiting
Patients suffering acute ARDS defined according to the Berlin Definition starting from severe stage with acute onset and (i) ratio partial arterial pressure of oxygen fraction of inspired oxygen inspired oxygen fraction (PaO2/ FiO2) ≤ 200 (ii) Bilateral opacities consistent with pulmonary edema on frontal chest radiograph, and (iii) requirement for positive pressure ventilation via an endotracheal tube or non-invasive ventilation (iv) no clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mm Hg (v) less than 96 hours from onset of ARDS (vi) less than 7 days from the initiation of mechanical ventilation will be treated by ECMO either within 24 hours to referral to an ARDS ECMO center or as rescue therapy after failure of conventional therapy.
Outcome measures have been chosen according to robustness and sensitivity to change. They are of high clinical impact and reflect the treatment effect desired by clinicians.
Primary efficacy endpoint: All cause mortality by 90-days.
Key secondary endpoints are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ECMO implantation immediately after ICU admission
Time frame: 90 days after study inclusion
90 day all cause mortality
Time frame: 1-14, 28 and 90 days after study inclusion
SOFA Organ Failure Scores
Time frame: within 90 days after study inclusion
Duration of mechanical ventilation
Time frame: 28 days after study inclusion
28 day all cause mortality
Time frame: overall length of stay
overall length of stay on ICU
Contact information is provided by the study sponsor or research team.
University Hospital Tuebingen
Other
Early Versus Late Initiation of ECMO Trial (ELIEO-Trial)
Acronym: ELIEO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06513949
Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Seattle, Washington, United States
View Trial DetailsNCT07726953
Acute Respiratory Distress Syndrome, Lung Diseases
Beijing, China
View Trial DetailsNCT07289711
Acute Respiratory Distress Syndrome, Lung Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT07595926
Acute Respiratory Distress Syndrome, Height
Amiens, France
View Trial Details